Other differentially-expressed genes could not be classified as components of a specific pathway, but are of great clinical impact in breast carcinoma, for example, ERβ with a 3.23-fold downregulation in effusions and MTA3, an estrogen-sensitive gene involved in E-cadherin regulation, with a 2.42- fold downregulation in effusions. This evidence concerns the gene ESR2 and breast carcinoma.